Desk›Healthcare› Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd
BSE 544210 · NSE EMCURE · ISIN INE168P01015 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹1,871.25
-0.43%
BSE close, 28 August 2026
₹35,493.90 cr
19.0 cr shares · Mid cap
₹7,807.88 cr
as published
43.8× · 12.55×
EPS ₹42.72 · BV ₹149.10
5,243.19 / 732.96
₹ cr, as filed
30
9 selected · 30%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -8.6% |
|---|---|
| Against 52-week low | +48.5% |
| Day change | -0.43% |
| Size band | Mid cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹42.72 |
|---|---|
| Price / earnings | 43.80× |
| Price / book | 12.55× |
| Book value — derived, price ÷ P/B | ₹149.10 |
| Return on equity | 28.65% |
| Operating margin | 25.13% |
| Net margin | 13.79% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 28.65%
- ROE as published
- 28.65%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 1,450.93 | 200.11 | 10.55 | 25.13% | 13.79% |
| Mar-26 · Q | 1,467.70 | 233.70 | 12.33 | 27.67% | 15.92% |
| FY25-26 | 5,243.19 | 732.96 | 38.67 | 24.97% | 13.98% |
Quarter on quarter
- Revenue, quarter on quarter
- -1.1%
- Net profit, quarter on quarter
- -14.4%
- Operating margin, quarter on quarter
- -254 bps
Disclosure profile 30 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Change in Management | 2 |
| Investor Presentation | 2 |
| Board Outcome | 1 |
| Credit Rating | 1 |
| Order / Contract | 1 |
| Press Release | 1 |
| Results | 1 |
| Selected sub-total | 9 |
| Procedural | |
| Analyst / Investor Meet | 8 |
| AGM / EGM | 3 |
| General | 3 |
| ESOP Allotment | 2 |
| Annual Report | 1 |
| BRSR | 1 |
| Newspaper Publication | 1 |
| Record Date | 1 |
| Trading Window | 1 |
| Procedural sub-total | 21 |
| Total | 30 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
30 filings · 9 selected · busiest 2026-08-06 and 2026-08-07
Filing rhythm · the twelve most recent
2026-08-282026-10-02
SelectedProcedural
Filings
30 in the window · 10 earlier on record
-
2 October 2026 ·
Award_of_Order_Receipt_of_Order
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulatory Order(s)
Company Update / Award of Order / Receipt of Order View filing →
-
29 September 2026 ·
Closure of Trading Window
Intimation of Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
25 September 2026 ·
Investor Presentation
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation
Company Update / Investor Presentation View filing →
-
23 September 2026 ·
Intimation Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015 - Change In Composition Of The Board Of The Company
Change in composition of the Board of the Company
Company Update / General View filing →
-
23 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Voting Results of the 45th Annual General Meeting of the Company along with the consolidated Report of the Scrutinizer
AGM/EGM / AGM View filing →
-
21 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 45th Annual General Meeting of the Members of the Company
AGM/EGM / AGM View filing →
-
11 September 2026 ·
Allotment of ESOP / ESPS
Allotment of 11,400 Equity Shares pursuant to exercise of ESOPs under Emcure - Employee Stock Option Scheme 2013
Company Update / Allotment of ESOP / ESPS View filing →
-
1 September 2026 ·
Intimation Under Regulations 30 And 36(1)(B) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dispatch of letter to the members whose e-mail addresses are not registered with the Company/Depository Participants
Company Update / General View filing →
-
1 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of schedule of Investor Meet on Friday, September 04, 2026
Company Update / Analyst / Investor Meet View filing →
-
1 September 2026 ·
Credit Rating
Reaffirmation of Credit Ratings by CARE Ratings Limited
Company Update / Credit Rating View filing →
-
28 August 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for the Financial Year 2025-26
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
28 August 2026 ·
Notice Of The 45Th Annual General Meeting
Notice of the 45th Annual General Meeting of Emcure Pharmaceuticals Limited
AGM/EGM / AGM View filing →
-
28 August 2026 ·
Reg. 34 (1) Annual Report.
Annual Report of the Company for the Financial Year 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
25 August 2026 ·
Allotment of ESOP / ESPS
Allotment of 19,100 Equity Shares pursuant to exercise of ESOPs under Emcure - Employee Stock Option Scheme 2013
Company Update / Allotment of ESOP / ESPS View filing →
-
12 August 2026 ·
Analyst / Investor Meet - Outcome
Transcript of Earnings Call - Q1 FY27
Company Update / Analyst / Investor Meet View filing →
-
7 August 2026 ·
Analyst / Investor Meet - Intimation
Analyst/ Investor Meet on Tuesday, September 22, 2026
Company Update / Analyst / Investor Meet View filing →
-
7 August 2026 ·
Analyst / Investor Meet - Intimation
Analyst/ Investor Meet on Thursday, September 17, 2026
Company Update / Analyst / Investor Meet View filing →
-
7 August 2026 ·
Analyst / Investor Meet - Intimation
Analyst/ Investor Meet on Tuesday, September 01, 2026
Company Update / Analyst / Investor Meet View filing →
-
7 August 2026 ·
Analyst / Investor Meet - Intimation
Analyst/ Investor Meet on Tuesday, August 18, 2026
Company Update / Analyst / Investor Meet View filing →
-
7 August 2026 ·
Analyst / Investor Meet - Intimation
Analyst/Investor Meet on Wednesday, August 12, 2026
Company Update / Analyst / Investor Meet View filing →
-
7 August 2026 ·
Newspaper Publication
Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Company Update / Newspaper Publication View filing →
-
6 August 2026 ·
Analyst / Investor Meet - Outcome
Audio recording of Earnings Call - Q1 FY27
Company Update / Analyst / Investor Meet View filing →
-
6 August 2026 ·
Intimation Of Date Of The 45Th Annual General Meeting And Record Date
Intimation of date of the 45th Annual General Meeting and Record Date for payment of Final Dividend on Equity Shares for the Financial Year March 31, 2026
Corp. Action / Record Date View filing →
-
6 August 2026 ·
Change in Management
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Change in composition of the Board of the Company
Company Update / Change in Management View filing →
-
6 August 2026 ·
Investor Presentation
Presentation on Unaudited Financial Results for the quarter ended June 30, 2026
Company Update / Investor Presentation View filing →
-
6 August 2026 ·
Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2026
Unaudited Financial Results (Standalone and consolidated) for the quarter ended June 30, 2026
Result / Financial Results View filing →
-
6 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting Held On August 06, 2026
Outcome of Board Meeting held on August 06, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
22 July 2026 ·
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Update On Completion Of Acquisition Of Shares Of Gennova Biopharmaceuticals Limited.
Update on completion of acquisition of shares of Gennova Biopharmaceuticals Limited
Company Update / General View filing →
-
21 July 2026 ·
Change in Management
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Completion of 2nd term of Independent Director
Company Update / Change in Management View filing →
-
20 July 2026 ·
Press Release / Media Release
Press Release titled "Emcure to Expand the Use of Poviztra for MASH Indication Following CDSCO Approval".
Company Update / Press Release / Media Release View filing →
RSS feed for Emcure Pharmaceuticals Ltd · the 50 most recent filings